**Supplementary data: Table S2. Assessment of antiviral T-cell responses in the context of kidney transplantation (KTRs without BKv reactivation)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Assessment of antiviral T-cell response** | Proliferation | TNFα secretion | TNFα/ IFNγ secretion |
| BKv (LT-Ag and VP1) stimulation (n*i*) | 16 | 16 | 16 |
| BKv (LT-Ag and VP1) CD4 - cell response (cell nb) | 3.04 [1.22-3.83] | 0.52 [0.03-1.87] | 0.15 [0.03-0.75] |
| No BKv-specific peptide response, n (%) | 6 (37.5) | 4 (25) | 7 (43.8) |
| BKv-specific response against LT-Ag or VP1 peptides, n (%) | 1 (6.2) | 6 (37.5) | 3 (18.7) |
| BKv-specific response against LT-Ag and VP1 peptides, n (%) | 9 (56.3) | 6 (37.5) | 6 (37.5) |
| BKv (LT-Ag and VP1) CD8 T-cell response (cell nb) | 3.76 [2.59-4.39] | 0.66 [0.03-1.62] | 0.032 [0.03-0.45] |
| No BKv-specific peptide response, n (%) | 3 (18.7) | 5 (31.3) | 7 (43.7) |
| BKv-specific response against LT-Ag or VP1 peptides, n (%) | 1 (6.3) | 4 (25) | 3 (18.8) |
| BKv-specific response against LT-Ag and VP1 peptides, n (%) | 12 (75) | 7 (43.7) | 6 (37.5) |
| Other viral peptide stimulations (n*i*) | 10 | 10 | 10 |
| CEF – CD8 T-cell response (cell nb) | 3.90 [3.09-4.73] | 0.68 [0.03-1.87] | 3.66 [1.28-8.03] |

BKv: BK-virus; n: number of patients; CEF: pool of cytomegalovirus, Epstein Barr virus and influenza virus peptides; cell nb: cell number. Continuous data are expressed in medians and interquartile ranges. *(i)* For each patient, two BKv-specific responses were analyzed, after stimulation with LT-Ag and VP1 peptides.